ACCOLATE (zafirlukast) by PharmaIN is leukotriene receptor antagonists [moa]. First approved in 1996.
Drug data last refreshed 10h ago · AI intelligence enriched 1mo ago
ACCOLATE (zafirlukast) is an oral leukotriene receptor antagonist approved in 1996 for asthma management. It works by blocking leukotriene receptors in the airways, reducing inflammation and bronchoconstriction. This small-molecule therapy is typically used as a maintenance or adjunctive treatment for persistent asthma.
Minimal commercial activity with only 21 Medicare claims annually signals a mature product with shrinking market presence and reduced team investment.
Leukotriene Receptor Antagonists
Leukotriene Receptor Antagonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Crossover Study of Zafirlukast in Preventing Allergen-induced Signs and Symptoms in Response to Cat Dander Challenge
Bioequivalence Study of Zafirlukast Tablets 20 mg of Dr. Reddy's Laboratories Limited Under Fasting Condition
Working on ACCOLATE offers limited career growth opportunity given zero linked job postings, minimal commercial spending ($8K Part D), and LOE-approaching lifecycle status. Roles on this team typically focus on market maintenance, managed-care negotiations, and defending market share against generics rather than innovation or expansion.
Worked on ACCOLATE at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo